Repligen (NASDAQ: RGEN) is a global bioprocessing company that develops and sells products used in the manufacturing of biological drugs. With a market capitalization of approximately $7.08 billion, Repligen's stock price has seen its value move between $109.50 and $175.77 over the past 52 weeks, indicating notable changes in its market valuation. Following the company's recent performance, Jefferies analyst Matthew Stanton has lowered the price target for Repligen to $142.00. At the time of the announcemen ...